Owing to the recent setbacks in vaccine and microbicide trails, novel strategies to slow the HIV-pandemic are desperately needed. Development of a small molecule that blocked a host process required for HIV-1 replication could provide such a strategy. Like all retroviruses, HIV-1 requires host proteins to complete its life cycle, and these intracellular host molecules represent an undeveloped pool of novel anti-HIV therapeutics. The goal of this application is to use functional proteomics to identify host proteins that are dispensable to the host but essential for viral replication. A generic proteomic screen would likely identify numerous host proteins induced by HIV-infection, most of which would be poor therapeutic candidates. A functional proteomics screen, which queries a subset of proteins with strong therapeutic potential, would greatly simplify the search for host targets;the host purinome has this potential. The purinome comprises any protein that binds purine- containing molecules (e.g. ATP, NADH), and it includes heat shock proteins, dehydrogenases, and protein kinases. Inhibition of purinome proteins forms the basis of many current therapies, including those targeting cancer, hypertension, and bacterial infections. The central hypothesis of this application states that inhibition of purinome proteins, which are induced or regulated by HIV-infection, will block HIV-1 replication. Our research team has designed a protein affinity media that captures the entire purinome through its purine-binding pocket. The proposed research will proceed in four broad steps: use SILAC (stable isotope labeling with amino acids in cell culture) to quantify purinome proteins induced by HIV-1 infection of THP1 and Jurkat cells (target identification);determine which purinome proteins are essential for HIV-1 replication (target validation);identify drugs that selectively compete validated targets from the purinome-binding resin (drug discovery);confirm that these compounds block HIV-replication in primary cells (drug validation). During this process, we will also identify host proteins that interact with HIV-1, and in the event that a viable purinome target and/or drug is not identified, viral biology will be advanced by a greater understanding of how HIV-1 interacts with its host. The proposed research uses innovative proteomics technology (SILAC) and an unconventional, yet validated, approach. First, conventional anti-HIV therapeutics inhibit virally-encoded proteins, which makes them more susceptible to the development of resistance. By targeting a host enzyme that is required for HIV-1 replication, it is likely that the virus will have to undergo more radical changes to offset the changes in the host milieu. Second, conventional drug discovery uses a reductionist approach to separately identify a target and a drug, while our approach combines the target/drug identification process, which makes discovery more efficient. At the completion of this project, our combination of experience and technology will enable us to characterize host purine-binding proteins that are essential for HIV-1 replication and identify several lead compounds that will inhibit host proteins necessary for HIV-1 replication.

Public Health Relevance

The proposed studies will discover a novel compound that inhibits an intracellular host protein and blocks HIV- 1 replication;this strategy will likely produce therapeutics that pose a surmountable burden to the development of HIV drug resistance. These compounds could be deployed in a microbicide. Page 21

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI090644-03
Application #
8272655
Study Section
Special Emphasis Panel (ZAI1-BP-A (M2))
Program Officer
Gupta, Kailash C
Project Start
2010-06-01
Project End
2014-05-31
Budget Start
2012-06-01
Budget End
2013-05-31
Support Year
3
Fiscal Year
2012
Total Cost
$432,020
Indirect Cost
$79,999
Name
Ohio State University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Alwarawrah, Yazan; Hughes, Philip; Loiselle, David et al. (2016) Fasnall, a Selective FASN Inhibitor, Shows Potent Anti-tumor Activity in the MMTV-Neu Model of HER2(+) Breast Cancer. Cell Chem Biol 23:678-88
Turner, Abigail Norris; Maierhofer, Courtney; Funderburg, Nicholas T et al. (2016) High levels of self-reported prescription opioid use by HIV-positive individuals. AIDS Care 28:1559-1565
Mates, Jessica M; de Silva, Suresh; Lustberg, Mark et al. (2015) A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4(+) T-cells. Retrovirology (Auckl) 7:1-5
Koopman, Jacob A; Marshall, Joanna M; Bhatiya, Aditi et al. (2015) Inhibition of Salmonella enterica biofilm formation using small-molecule adenosine mimetics. Antimicrob Agents Chemother 59:76-84
Rathore, Abhay P S; Haystead, Timothy; Das, Pratyush K et al. (2014) Chikungunya virus nsP3 & nsP4 interacts with HSP-90 to promote virus replication: HSP-90 inhibitors reduce CHIKV infection and inflammation in vivo. Antiviral Res 103:7-16
Keim, Sarah A; Hogan, Joseph S; McNamara, Kelly A et al. (2013) Microbial contamination of human milk purchased via the Internet. Pediatrics 132:e1227-35
Barrott, Jared J; Hughes, Philip F; Osada, Takuya et al. (2013) Optical and radioiodinated tethered Hsp90 inhibitors reveal selective internalization of ectopic Hsp90 in malignant breast tumor cells. Chem Biol 20:1187-97
Barrott, Jared J; Haystead, Timothy A J (2013) Hsp90, an unlikely ally in the war on cancer. FEBS J 280:1381-96
Carlson, David A; Franke, Aaron S; Weitzel, Douglas H et al. (2013) Fluorescence linked enzyme chemoproteomic strategy for discovery of a potent and selective DAPK1 and ZIPK inhibitor. ACS Chem Biol 8:2715-23
Edwards, Jessica A; Kemski, Megan M; Rappleye, Chad A (2013) Identification of an aminothiazole with antifungal activity against intracellular Histoplasma capsulatum. Antimicrob Agents Chemother 57:4349-59

Showing the most recent 10 out of 13 publications